United Therapeutics
UTHR
374 hedge funds and large institutions have $4.76B invested in United Therapeutics in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 144 increasing their positions, 126 reducing their positions, and 29 closing their positions.
38% more call options, than puts
Call options by funds: $35.1M | Put options by funds: $25.4M
14% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 126
7% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 29
0% more funds holding
Funds holding: 374 → 374 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less capital invested
Capital invested by funds: $4.88B → $4.76B (-$119M)
3.82% less ownership
Funds ownership: 100.73% → 96.91% (-3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$29.6M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$20.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.6M |
| 4 |
BlackRock
New York
|
+$12.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$43.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.1M |
| 3 |
JP Morgan Chase
New York
|
-$28.8M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$19.7M |
| 5 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$18.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
401
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$2K | -18 | Closed |
|
|
WAM
402
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | -$1.54K | -14 | -78% |
|
|
PHK
403
Point72 Hong Kong
Hong Kong
| – | +$220 | +2 | New |
|
UTHR Hedge Fund Activity: Q2 2018 in Review
374 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2018, worth a combined $4.76B — down 2.4% from $4.88B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new UTHR positions and 29 closed out — a net gain of 2 holders — while 144 added to existing stakes and 126 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $29.6M. The largest seller was Armistice Capital, exiting entirely with an estimated $43.6M sold.
- 374 institutional investors held United Therapeutics (UTHR) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $4.76B of United Therapeutics stock for Q2 2018, down 2.4% quarter-over-quarter.
- 31 funds opened new United Therapeutics positions in Q2 2018 and 29 closed out, a net change of +2 holders.
- The largest United Therapeutics buyer in Q2 2018 was AQR Capital Management, an estimated $29.6M added.
- The largest United Therapeutics seller in Q2 2018 was Armistice Capital, an estimated $43.6M sold.
Based on aggregated 13F filings for Q2 2018.